Life Science Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Life Science Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reaction
Collaborative to study unanticipated serious adverse drug events using enTRUST
January 25th, 2005
First Genetic Trust (FGT) announced that the U.S. Food and Drug Administration (FDA), Vanderbilt University Medical Center, and GlaxoSmithKline (GSK) will take part in a postmarketing clinical research effort using FGT's enTRUST genetic banking and research technology to study the genetic basis for drug-induced Long QT, a well-known side effect for many different classes of drugs. Patients who exhibit Long QT are at risk of developing problem heart arrhythmias that may, in rare cases, lead to sudden death. Using FGT's system, GSK is recruiting Long QT patients electronically through Vanderbilt and a network of referral sites, and using their...
Source: Life Science Weekly (2005-01-25)
|
